# A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

> **NCT07381829** · PHASE1 · RECRUITING · sponsor: **HC Biopharma Inc.** · enrollment: 328 (estimated)

## Conditions studied

- Advanced Solid Tumor Cancer

## Interventions

- **DRUG:** HC010
- **DRUG:** Paclitaxel (Chemotherapy)
- **DRUG:** Pemetrexed
- **DRUG:** Etoposide
- **DRUG:** Carboplatin/Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07381829
- **Lead sponsor:** HC Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 328 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381829, "A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07381829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*